- Home
- MIRM vs MATX Comparison
MIRM vs MATX Comparison
Compare MIRM & MATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | MATX |
|---|---|---|
| Founded | 2018 | 1882 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.2B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MIRM | MATX |
|---|---|---|
| Price | $107.51 | $200.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | $119.85 | ★ $163.33 |
| AVG Volume (30 Days) | ★ 595.3K | 300.6K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.83% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 1.85 |
| Revenue | $19,138,000.00 | ★ $3,344,500,000.00 |
| Revenue This Year | $26.22 | $4.65 |
| Revenue Next Year | $22.04 | $4.31 |
| P/E Ratio | ★ N/A | $109.74 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $50.25 | $86.97 |
| 52 Week High | $130.00 | $230.74 |
Technical Indicators
Market Signals| Indicator | MIRM | MATX |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 43.74 |
| Support Level | $87.93 | $189.60 |
| Resistance Level | $114.99 | $205.48 |
| Average True Range (ATR) | 4.52 | 7.16 |
| MACD | -1.87 | -2.16 |
| Stochastic Oscillator | 2.05 | 17.09 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About MATX Matson Inc.
Matson Inc is engaged in providing ocean transportation and logistics services. The company has two reportable business segments: Ocean Transportation and Logistics. The Ocean Transportation segment provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific. The Logistics segment offers long-haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.